Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.
Spyglass Pharma provides medicine for ophthalmic diseases.
Exo is a medical device startup which develops handheld ultrasound devices and AI for imaging and therapeutic applications.
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.
Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Bambusa Therapeutics operates as biotechnology company.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
MARS provides digital financial services with unique card options and rewards programs.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Life Science. The firm invests across 22 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include Pahr Therapeutics, Spyglass Pharma, Exo, Stylus Medicine, Imbria Pharmaceuticals. These companies were founded in 2020 or later.